Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.94 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.94 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.94 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.94 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.94 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ku-0063794 SCHEMBL290211 | 0.97 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| Ku-0063794 SCHEMBL29454796 | 0.97 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| Ku-0063794 SCHEMBL29350060 | 0.97 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| Ku-0063794 SCHEMBL290208 | 0.97 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL22787101 | 0.91 | MTOR (0.84) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL14239586 | 0.91 | MTOR (0.86) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL2906431 | 0.90 | MTOR (0.90) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL10092312 | 0.89 | MTOR (0.86) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL4748699 | 0.88 | MTOR (0.85) | MTORKCNH2PIK3CDPIK3CARICTOR | |
| SCHEMBL4179308 | 0.88 | MTOR (1.00) | MTORKCNH2PIK3CDPIK3CARICTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MTOR 1/4885KCNH2 4409/4885PIK3CD 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.